MCM
RYTM icon

MAI Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

MAI Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$236K Buy
2,710
+2,708
+135,400% +$263K ﹤0.01% 1381
2025
Q4 		$215 Sell
2
-1,855
-100% -$197K ﹤0.01% 4027
2025
Q3 		$188K Buy
+1,857
New +$172K ﹤0.01% 1292

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

MAI Capital Management's RYTM Position: Q1 2026 in Review

MAI Capital Management increased its Rhythm Pharmaceuticals (RYTM) stake by 135,400% in Q1 2026, buying an estimated $263K and bringing the position to 2,710 shares worth $236K. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

MAI Capital Management first reported a position in RYTM in Q3 2025 and has held it in 3 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • MAI Capital Management held 2,710 shares of Rhythm Pharmaceuticals worth $236K as of Q1 2026.
  • MAI Capital Management bought 2,708 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $263K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #1381 holding.
  • MAI Capital Management first reported a position in Rhythm Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.